Comparative Pharmacology
Head-to-head clinical analysis: INCIVEK versus XOFLUZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCIVEK versus XOFLUZA.
INCIVEK vs XOFLUZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
Baloxavir marboxil is a prodrug that is converted to baloxavir acid, which inhibits the cap-dependent endonuclease activity of the influenza virus polymerase acidic protein, thereby preventing viral mRNA transcription and replication.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
40 mg orally once as a single dose; for patients weighing ≥80 kg, 80 mg orally once as a single dose.
None Documented
None Documented
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
The terminal elimination half-life of baloxavir marboxil is approximately 79.1 hours (range 53–107 hours), supporting single-dose therapy for influenza.
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Baloxavir marboxil is primarily excreted via feces (80.1%) and urine (14.7%) after oral administration, with <1% as unchanged drug in urine.
Category C
Category C
Antiviral
Antiviral